Literature DB >> 24296845

Medication-use evaluation with a Web application.

Muriel Burk1, Von Moore, Peter Glassman, Chester B Good, Thomas Emmendorfer, Thomas C Leadholm, Francesca Cunningham.   

Abstract

PURPOSE: A Web-based application for coordinating medication-use evaluation (MUE) initiatives within the Veterans Affairs (VA) health care system is described.
SUMMARY: The MUE Tracker (MUET) software program was created to improve VA's ability to conduct national medication-related interventions throughout its network of 147 medical centers. MUET initiatives are centrally coordinated by the VA Center for Medication Safety (VAMedSAFE), which monitors the agency's integrated databases for indications of suboptimal prescribing or drug therapy monitoring and adverse treatment outcomes. When a pharmacovigilance signal is detected, VAMedSAFE identifies "trigger groups" of at-risk veterans and uploads patient lists to the secure MUET application, where locally designated personnel (typically pharmacists) can access and use the data to target risk-reduction efforts. Local data on patient-specific interventions are stored in a centralized database and regularly updated to enable tracking and reporting for surveillance and quality-improvement purposes; aggregated data can be further analyzed for provider education and benchmarking. In a three-year pilot project, the MUET program was found effective in promoting improved prescribing of erythropoiesis-stimulating agents (ESAs) and enhanced laboratory monitoring of ESA-treated patients in all specified trigger groups. The MUET initiative has since been expanded to target other high-risk drugs, and efforts are underway to refine the tool for broader utility.
CONCLUSION: The MUET application has enabled the increased standardization of medication safety initiatives across the VA system and may serve as a useful model for the development of pharmacovigilance tools by other large integrated health care systems.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24296845     DOI: 10.2146/ajhp130252

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  5 in total

1.  Space-Time Cluster Analysis to Detect Innovative Clinical Practices: A Case Study of Aripiprazole in the Department of Veterans Affairs.

Authors:  Robert B Penfold; James F Burgess; Austin F Lee; Mingfei Li; Christopher J Miller; Marjorie Nealon Seibert; Todd P Semla; David C Mohr; Lewis E Kazis; Mark S Bauer
Journal:  Health Serv Res       Date:  2016-12-22       Impact factor: 3.402

2.  Assessing Hepatitis B Reactivation Risk With Rituximab and Recent Intravenous Immunoglobulin Therapy.

Authors:  Claire Dysart; Karine Rozenberg-Ben-Dror; Mariscelle Sales
Journal:  Open Forum Infect Dis       Date:  2020-03-02       Impact factor: 3.835

Review 3.  A Scoping Review of the Quality and the Design of Evaluations of Mobile Health, Telehealth, Smart Pump and Monitoring Technologies Performed in a Pharmacy-Related Setting.

Authors:  Darrin Baines; Imandeep K Gahir; Afthab Hussain; Amir J Khan; Philip Schneider; Syed S Hasan; Zaheer-Ud-Din Babar
Journal:  Front Pharmacol       Date:  2018-07-26       Impact factor: 5.810

4.  Drug Use Evaluation of Beta-Blockers in Medical Wards of Nedjo General Hospital, Western Ethiopia.

Authors:  Ginenus Fekadu; Firomsa Bekele; Kumera Bekele; Sagni Hanbisa; Gemechis Belay; Mudasir Maqbool
Journal:  Cardiovasc Ther       Date:  2020-05-22       Impact factor: 3.023

5.  Preventing Hepatitis B Reactivation During Anti-CD20 Antibody Treatment in the Veterans Health Administration.

Authors:  A Jasmine Bullard; Francesca E Cunningham; Bryan D Volpp; Elliott Lowy; Lauren A Beste; Bernadette B Heron; Mark Geraci; Julia M Hammond; Kourtney LaPlant; Elise A Stave; Marsha J Turner; Meghan C O'Leary; Michael J Kelley; Christine M Hunt
Journal:  Hepatol Commun       Date:  2018-08-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.